Drug intelligence / Profile preview

177Lu-GQ9001

Development stage: Unknown
Lead developer: GeneQuantum Biosciences
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

177Lu-GQ9001 is a next-generation radionuclide drug conjugate (RDC) developed by GeneQuantum Healthcare. It consists of a high-affinity nanobody targeting Prostate-Specific Membrane Antigen (PSMA) conjugated to the beta-emitting radioisotope Lutetium-177 (177Lu) via a proprietary linker and the intelligent Ligase-Dependent Conjugation (iLDC) platform. Designed for the treatment of metastatic castration-resistant prostate cancer (mCRPC), 177Lu-GQ9001 aims to optimize pharmacokinetics by enhancing tumor accumulation and retention while minimizing renal uptake compared to small-molecule radioligands like Pluvicto (177Lu-PSMA-617). Early clinical data indicates a favorable safety profile and potent therapeutic efficacy, including significant reductions in PSA levels and superior tumor-to-background ratios in patients.

Other names: 177Lu-labeled anti-PSMA nanobody-based RDC

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on 177Lu-GQ9001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 177Lu-GQ9001.

Explore the full profile